EBITDA for IDEXX Laboratories (IDXX)
According to IDEXX Laboratories's latest reported financial statements, the company's current EBITDA (TTM) is $1.51B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$1.51B
YoY change
+15.1%
5Y CAGR
+13.1%
Peak year (2025)
$1.47B
Cumulative EBITDA
$12.45B
EBITDA history chart for IDEXX Laboratories (IDXX) from 1991 to 2025
EBITDA history table for IDEXX Laboratories (IDXX) from 1991 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $1.47B | +15.1% | ||
| 2024 | $1.28B | +4.8% | ||
| 2023 | $1.22B | +20.0% | ||
| 2022 | $1.01B | -2.4% | ||
| 2021 | $1.04B | +31.0% | ||
| 2020 | $793.81M | +23.3% | ||
| 2019 | $643.68M | +11.8% | ||
| 2018 | $575.66M | +14.8% | ||
| 2017 | $501.42M | +16.2% | ||
| 2016 | $431.69M | +16.6% | ||
| 2015 | $370.29M | +15.8% | ||
| 2014 | $319.81M | -0.8% | ||
| 2013 | $322.34M | +1.9% | ||
| 2012 | $316.18M | +11.0% | ||
| 2011 | $284.75M | +13.7% | ||
| 2010 | $250.50M | +10.7% | ||
| 2009 | $226.23M | +1.2% | ||
| 2008 | $223.59M | +26.1% | ||
| 2007 | $177.28M | +12.4% | ||
| 2006 | $157.75M | +12.9% | ||
| 2005 | $139.70M | +10.5% | ||
| 2004 | $126.46M | +57.3% | ||
| 2003 | $80.39M | +22.1% | ||
| 2002 | $65.81M | -16.5% | ||
| 2001 | $78.78M | +8.3% | ||
| 2000 | $72.73M | +13.6% | ||
| 1999 | $64.00M | +41.9% | ||
| 1998 | $45.10M | +351.0% | ||
| 1997 | $10.00M | -82.6% | ||
| 1996 | $57.40M | +48.7% | ||
| 1995 | $38.60M | +41.4% | ||
| 1994 | $27.30M | +54.2% | ||
| 1993 | $17.70M | +105.8% | ||
| 1992 | $8.60M | +138.9% | ||
| 1991 | $3.60M | — |
EBITDA values are taken from IDEXX Laboratories's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, IDEXX Laboratories (IDXX) reported EBITDA of $1.47B – grew 15.1% year-over-year.
Through 2020–2025 (5 years), IDEXX Laboratories EBITDA delivered a +13.1% annualised rate; sustaining 3 straight years of year-over-year growth.
Across the available history, EBITDA reached its high of $1.47B in 2025 and its low of $3.60M in 1991.
Among 8 Healthcare peers, IDEXX Laboratories (IDXX) ranks 9th; the peer median for EBITDA is $24.21B.
IDEXX Laboratories EBITDA by Year
IDEXX Laboratories EBITDA 2025: $1.47B
IDEXX Laboratories EBITDA in 2025 was $1.47B, grew 15.1% from 2024. This figure represents the highest annual value in the available history.
IDEXX Laboratories EBITDA 2024: $1.28B
IDEXX Laboratories EBITDA in 2024 was $1.28B, edged up 4.8% from 2023.
IDEXX Laboratories EBITDA 2023: $1.22B
IDEXX Laboratories EBITDA in 2023 was $1.22B, grew 20.0% from 2022.
IDEXX Laboratories EBITDA 2022: $1.01B
IDEXX Laboratories EBITDA in 2022 was $1.01B, edged down 2.4% below 2021.
IDEXX Laboratories EBITDA 2021: $1.04B
IDEXX Laboratories EBITDA in 2021 was $1.04B.
See more financial history for IDEXX Laboratories (IDXX).
Sector peers — EBITDA
Companies in the same sector as IDEXX Laboratories, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is IDEXX Laboratories's EBITDA?
- Latest reported EBITDA for IDEXX Laboratories (IDXX) is $1.51B (period ending December 31, 2025).
How has IDEXX Laboratories EBITDA changed year-over-year?
- IDEXX Laboratories (IDXX) EBITDA changed +15.1% year-over-year on the latest annual filing.
What is the long-term growth rate of IDEXX Laboratories EBITDA?
- IDEXX Laboratories (IDXX) EBITDA compound annual growth rate is +13.1% over the most recent 5 years available.
When did IDEXX Laboratories EBITDA hit its highest annual value?
- IDEXX Laboratories EBITDA reached its highest annual value of $1.47B in 2025.
What was IDEXX Laboratories EBITDA in 2024?
- IDEXX Laboratories (IDXX) EBITDA in 2024 was $1.28B.
What was IDEXX Laboratories EBITDA in 2025?
- IDEXX Laboratories (IDXX) EBITDA in 2025 was $1.47B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
IDXX Overview
Company profile, financial tools, and key metrics
IDXX Revenue Counter
Earns $136.47 every second. See per minute, hour, and day.
IDXX Earnings Counter
Earns $33.60 per second net profit. See per minute, hour, and day.
IDXX Economic Scale
Exceeds Aruba's GDP. Compare with world economies.
IDXX What If Invested
What if you had invested $1,000? See historical returns from any date.
IDXX How It Makes Money
Discover visual breakdown of $4.30B in revenue — where it comes from and where it goes.
IDXX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
IDXX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
IDXX Daily Price Character
Explosive · 50.9% historical win rate (green days). Streaks & record days.
IDXX Buybacks
2.25% TTM buyback yield. Shareholder yield & SBC comparison.
IDXX Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.